Rhythm Pharmaceuticals Inc.
RYTM
Market Cap$2.31B
Close$
$-25.30
166.7% downside
Current Fair Value
166.7% downsideOvervalued by 166.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.31 Billion |
|---|---|
| Enterprise Value | $2.22 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-4.68 |
| Beta | 1.27 |
| Outstanding Shares | 60,972,909 |
| Avg 30 Day Volume | 576,065 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -8.45 |
|---|---|
| PEG | -4.94 |
| Price to Sales | 37.96 |
| Price to Book Ratio | 37.96 |
| Enterprise Value to Revenue | 24.17 |
| Enterprise Value to EBIT | -8.18 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 1.76 |
Revenue Sources
No data
ESG Score
No data
About Rhythm Pharmaceuticals Inc.
90 employees
CEO: Hunter Smith Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the mel...